HHS Rulemaking On Price Disclosures In DTC Ads Supported In Senate-Passed Bill
US congressional action comes as HHS forwards proposed rule on enhancing drug pricing transparency to Office of Management and Budget for review.
You may also be interested in...
Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.
Even though measure was blocked in Congress, it may still advance through regulation.
CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.